AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
TL;DR
Current evidence through July 2026 is summarized, plausible mechanisms of resistance and biomarker evolution are examined, and a cautious, modality-specific framework for future clinical development is proposed.
This article systematically elaborates the molecular structure, expression regulatory mechanisms and clinicopathological value of CLDN18.2 based on the data of 58 global clinical trials, and analyzes the current status, existing problems in testing standardization and drug development.
A central argument about treatment sequencing is advanced: because CLDN18.2 expression declines progressively under therapeutic pressure, continuous target-plus-chemotherapy acts on an eroding antigen substrate, for patients with high, homogeneous baseline expression, an early intensive induction followed by CLDN18.2-d...
Penpulimab (AK105) is a novel Fc-engineered, humanised IgG₁ monoclonal antibody targeting programmed cell death protein-1 (PD-1). Unlike conventional PD-1 inhibitors, penpulimab has been designed to eliminate Fcγ receptor and complement C1q binding, thereby reducing Fc-mediated effector functions while maintaining anti...
The clinical management of adrenocortical carcinoma (ACC) has long been defined by its resistance to conventional therapies. Since the FIRM-ACT trial established the combination of etoposide, doxorubicin, and cisplatin plus mitotane (EDP-M) as the frontline standard, overall survival for metastatic patients has remaine...
The biological basis of CLDN18.2 accessibility is discussed, emerging imaging and theranostic strategies are summarized, and the evolving role of molecular imaging in patient stratification and imaging-informed precision oncology is examined.
Despite recent therapeutic advances, durable disease control in small cell lung cancer (SCLC) remains challenging, particularly after relapse following platinum-based chemo-immunotherapy. Lurbinectedin, a selective inhibitor of oncogenic transcription, has emerged as a novel therapeutic agent with a distinct mechanism...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.